View Author
patient cancer study treatment survival trial radiotherapy hrqol idh 1 mutations analysis mutation prognostic tumor scale chemotherapy glioblastoma temozolomide eortc score factor status erlotinib group brain qlq-bn baseline response oncol van den research outcome month promoter table result quality qlq-bn 20 idh 1 control arm phase oncology anaplastic hrqol scores glioma idh 2 mutations cycle mgmt promoter methylation presence questionnaire control performance performance status erlotinib arm model methylation follow-up adjuvant 6- month pfs tumour oligodendroglioma prognostic factors toxicity value expression surgery future eiaed prognostic value bene fit number progression qlq-c sample egfrviii pcv chemotherapy signi stupp motor dysfunction response rate resection
7 Most Recent Publications
|
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients
(Article)
Taphoorn, M.J. Claassens, L. Aaronson, N.K. Coens, C. Mauer, M. Osoba, D. Stupp, R. Mirimanoff, R.O. Bent, M.J. van den Bottomley, A. |
2010-04-01
|
|
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
(Article)
Bent, M.J. van den Dubbink, H.J. Marion, R. van Kros, J.M. Dinjens, W.N.M. Gorlia, T. Sanson, M. Marie, Y. Brandes, A. Taphoorn, M.J. Wesseling, P. Frenay, M. Tijssen, C.C. Lacombe, D. Idbaih, A. |
2010-03-01
|
|
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
(Article)
Stupp, R. Hegi, M.E. Hau, P. Brandes, A. Gijtenbeek, J. Marosi, C. Vecht, C.J. Mokhtari, K. Wesseling, P. Villa, S. Eisenhauer, E. Gorlia, T. Mason, W.P. Weller, M. Lacombe, D. Cairncross, J.G. Mirimanoff, R.O. Bent, M.J. van den Taphoorn, M.J. Janzer, R.C. Ludwin, S.K. Allgeier, A. Fisher, B. Belanger, K. |
2009-05-01
|
|
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
(Article)
Bent, M.J. van den Brandes, A. Armand, J.-P. Taphoorn, M.J. Tosoni, A. Kletzl, H. Klughammer, B. Lacombe, D. Gorlia, T. Rampling, R. Kouwenhoven, M.C.M. Kros, J.M. Carpentier, A.F. Clement, P.M.J. Frenay, M. Campone, M. Baurain, J.F. |
2009-03-10
|
|
In reply
(Article)
Taphoorn, M.J. Bent, M.J. van den Mauer, M. Bottomley, A. |
2008-09-15
|
|
The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: Results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study
(Article)
Mauer, M. Stupp, R. Mirimanoff, R.O. Forsyth, P. Bent, M.J. van den Weller, M. Bottomley, A. Taphoorn, M.J. Coens, C. Osoba, D. Marosi, C. Wong, R. Witte, O. de Cairncross, J.G. Efficace, F. |
2007-07-31
|
|
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972
(Article)
Bent, M.J. van den Chinot, O. Boogerd, W. Bravo Marques, J. Taphoorn, M.J. Kros, J.M. Rijt, C.C.D. van der Vecht, C.J. Beule, N. de Baron, B. |
2003-01-01
|
